A Phase 2 interventional study of Bimagrumab and Semaglutide in Obesity, Obese and Overweight or Obesity, sponsored by Eli Lilly and Company. Completed at 26 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Obesity by Eli Lilly and Company — 31 open to participants now, 55 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 36th largest by enrollment of the 117 interventional ones that give a count, is one of 10 that started in 2022, is one of 22 in phase 2, and was the 24th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →31 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Brazil, China and 7 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65 · Healthy volunteers
Eli Lilly and Company · Sites in United States
Ages 18–60 · Women only · Healthy volunteers
Eli Lilly and Company · Sites in United States
Ages 18–70
By country, each count listing its studies:
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 507 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 267 across the 117 interventional studies. Of the 61 that completed or were terminated, 29 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
29 of the studies in Obesity by Eli Lilly and Company that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06662383Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | 2026-11 |
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07232719Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | 2027-06 |
Add all 29 to your calendar (.ics) → With an account.
Among the 118 studies in Obesity by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
This study investigates if bimagrumab in addition to semaglutide is able to preserve/increase muscle mass in the presence of weight and/or fat mass loss.
Key Inclusion Criteria:
Men and women between 18 and 80 years, inclusive; women of (defined as those who are not or post-surgical sterilization) must meet both of the following criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64.
Other: Placebo
Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64.
Biological: Bimagrumab
Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64.
Biological: Bimagrumab
Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 71: 1.0 mg
Drug: Semaglutide · Other: Placebo
Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 12: 1.0 mg * Weeks 13 to 16: 1.7 mg * Weeks 17 to 71: 2.4 mg
Drug: Semaglutide · Other: Placebo
Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 71: 1.0 mg
Biological: Bimagrumab · Drug: Semaglutide
Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 12: 1.0 mg * Weeks 13 to 16: 1.7 mg * Weeks 17 to 71: 2.4 mg
Biological: Bimagrumab · Drug: Semaglutide
Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 71: 1.0 mg
Biological: Bimagrumab · Drug: Semaglutide
Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 12: 1.0 mg * Weeks 13 to 16: 1.7 mg * Weeks 17 to 71: 2.4 mg
Biological: Bimagrumab · Drug: Semaglutide
Human monoclonal antibody to the activin receptor type II
Glucagon-like peptide-1 (GLP-1) receptor agonist
Also known as: Wegovy, Ozempic
Placebo
Change From Baseline in Body Weight at Week 48
Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, Week 48
Change From Baseline in Waist Circumference at Week 48
Waist circumference was measured in standing position with a non-stretchable measuring tape to the nearest 0.1 centimeter (cm). Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, Week 48
Change From Baseline in Waist Circumference at Week 72
Waist circumference was measured in standing position with a non-stretchable measuring tape to the nearest 0.1 cm. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, Week 72
Change From Baseline in Total Body Fat Mass in Kilograms (kg) at Week 48
Change from baseline in total body fat mass in kg was assessed by Dual energy X-ray absorptiometry (DXA). Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, Week 48
Change From Baseline in Total Body Fat Mass in kg at Week 72
Change from baseline in total body fat mass in kg was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, Week 72
Percent Change From Baseline for Fat Mass by DXA at Week 48
Percent change from baseline for fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, Week 48
Percent Change From Baseline for Fat Mass by DXA at Week 72
Percent change from baseline for fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, Week 72
Change From Baseline in Visceral Adipose Tissue (VAT), Subcutaneous Adipose Tissue (SAT) and Trunk Fat Mass by DXA at Week 48
Change from baseline in VAT, SAT and trunk fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, Week 48
Change From Baseline in VAT, SAT and Trunk Fat Mass by DXA at Week 72
Change from baseline in VAT, SAT and trunk fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, Week 72
Percentage of Participants With Reduction in Waist Circumference Greater Than or Equal to (≥) 5 cm at Week 48
Waist circumference was measured in a standing position with a non-stretchable measuring tape to the nearest 0.1 cm. Only participants with non-missing baseline value were included in analysis.
Time frame: Week 48
Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48
Body weight was measured in kgs to the nearest 0.1 kg. Only participants with non-missing baseline value were included in analysis.
Time frame: Week 48
Percentage of Participants With Reduction in Fat Mass ≥ 5% ≥ 10% ≥ 15% by DXA at Week 48
Only participants with non-missing baseline value were included in analysis.
Time frame: Week 48
Percentage of Participants Achieving Fat Mass ≥ 10% Reduction With <5% Decrease in Lean Mass by DXA at Week 48
Only participants with non-missing baseline value were included in analysis.
Time frame: Week 48
Percentage of Participants Achieving >5 kg Weight Loss and Fat Loss Index (FLI) of >70%, >80%, and >90% by DXA at Week 48
Fat Lost Index = % change in fat mass/% change in lean mass + % change in fat mass. Only participants with non-missing baseline value were included in analysis.
Time frame: Week 48
Change From Baseline in Body Fat Mass by Bioelectrical Impedance Analysis (BIA) at Week 48
Change from baseline in body fat mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
Time frame: Baseline, Week 48
Change From Baseline in Body Fat Mass by BIA at Week 72
Change from baseline in body fat mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
Time frame: Baseline, Week 72
Percent Change From Baseline in Body Fat by BIA at Week 48
Percent change from baseline in Body fat was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
Time frame: Baseline, Week 48
Percent Change From Baseline in Body Fat by BIA at Week 72
Percent change from baseline in Body fat was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
Time frame: Baseline, Week 72
Change From Baseline in Lean Mass by DXA at Week 48
Change from baseline in lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, Week 48
Change From Baseline in Lean Mass by DXA at Week 72
Change from baseline in lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, Week 72
Percent Change From Baseline in Lean Body Mass by DXA at Week 48
Percent change from baseline in lean body mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, Week 48
Percent Change From Baseline in Lean Body Mass by DXA at Week 72
Percent change from baseline in lean body mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, Week 72
Percent Change From Baseline in Appendicular Lean Mass by DXA at Week 48
Percent change from baseline in appendicular lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, Week 48
Percent Change From Baseline in Appendicular Lean Mass by DXA at Week 72
Percent change from baseline in appendicular lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, Week 72
Change From Baseline in Lean Mass (kg) by BIA at Week 48
Change from baseline in lean mass (kg) was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
Time frame: Baseline, Week 48
Change From Baseline in Lean Mass (kg) by BIA at Week 72
Change from baseline in lean mass (kg) was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
Time frame: Baseline, Week 72
Percent Change From Baseline in Lean Body Mass by BIA at Week 48
Percent change from baseline in lean body mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
Time frame: Baseline, Week 48
Percent Change From Baseline in Lean Body Mass by BIA at Week 72
Percent change from baseline in lean body mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
Time frame: Baseline, Week 72
Percentage of Participants With Body Mass Index (BMI) Categories at Baseline and Week 48
BMI categories: i. Healthy weight: 18.5 kilograms (kg)/meter (m)² to 24.9 kg/m² ii. Overweight: 25 kg/m² to 29.9 kg/m² iii. Obesity class 1: 30 kg/m² to 34.9 kg/m² iv. Obesity class II: 35 kg/m² to 39.9 kg/m² v. Obesity class III: ≥ 40 kg/m2
Time frame: Baseline, Week 48
Percentage of Participants With Baseline Waist-to-Height Ratio (WtHR) Category of <0.5 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48
WHtR ratio categories: \<0.5; 0.5-0.59; ≥0.6
Time frame: Baseline up to 48 weeks
Percentage of Participants With Baseline WtHR Category of 0.5-0.59 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48
WHtR ratio categories: \<0.5; 0.5-0.59; ≥0.6
Time frame: Baseline up to 48 weeks
Percentage of Participants With Baseline WtHR Category ≥0.6 Having Change From Baseline in Waist-to-Height Ratio (WHtR Ratio) Categories at Week 48
WHtR ratio categories: \<0.5; 0.5-0.59; ≥0.6
Time frame: Baseline up to 48 weeks
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 48
HbA1c is the glycosylated fraction of hemoglobin A. It is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Time frame: Baseline, 48 weeks
Change From Baseline in Quality of Life Short Form 36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score at Week 24
The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores.
Time frame: Baseline, Week 24
Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score Week 24
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into (mental component score \[MCS\] and physical component score \[PCS\] to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.
Time frame: Baseline, Week 24
Change From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 48
The SF-36v2 acute form assesses HRQoL on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10 items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores
Time frame: Baseline, Week 48
Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 48
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into MCS and PCS to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.
Time frame: Baseline, Week 48
Change From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 72
The SF-36v2 acute form assesses HRQoL on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10 items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores
Time frame: Baseline, Week 72
Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 72
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into MCS and PCS to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.
Time frame: Baseline, Week 72
Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Score and Total Score at Week 24
The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'
Time frame: Baseline, Week 24
Change From Baseline in IWQOL-Lite-CT Physical Function Score and Total Score at Week 48
The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'
Time frame: Baseline, Week 48
Change From Baseline in IWQOL-Lite-CT Physical Function Score and Total Score at Week 72
The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'
Time frame: Baseline, Week 72
| Milestone | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Started | 56 | 56 | 57 | 56 | 57 | 56 | 56 | 56 | 57 |
| Safety analysis population (received at least 1 dose of study drug) | 55 | 56 | 57 | 55 | 56 | 56 | 55 | 56 | 55 |
| Completed | 22 | 25 | 27 | 33 | 39 | 28 | 35 | 37 | 35 |
| Not completed | 34 | 31 | 30 | 23 | 18 | 28 | 21 | 19 | 22 |
| Withdrew: Adverse event | 8 | 12 | 9 | 4 | 6 | 8 | 3 | 6 | 1 |
| Withdrew: Lost to follow-up | 7 | 4 | 6 | 4 | 5 | 9 | 2 | 2 | 6 |
| Withdrew: Non-compliance with study requirements | 3 | 2 | 3 | 3 | 0 | 3 | 2 | 1 | 4 |
| Withdrew: Withdrawal by subject | 13 | 10 | 8 | 10 | 7 | 6 | 8 | 10 | 7 |
| Withdrew: Physician decision | 0 | 1 | 1 | 0 | 0 | 1 | 4 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 2 |
| Withdrew: Other | 3 | 2 | 2 | 1 | 0 | 1 | 1 | 0 | 2 |
Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| kilogram (kg) | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Body Weight at Week 48 | -3.31 ± 1.39 | -5.99 ± 1.42 | -9.25 ± 1.33 | -9.76 ± 1.25 | -14.24 ± 1.17 | -12.73 ± 1.29 | -14.31 ± 1.34 | -13.86 ± 1.29 | -17.79 ± 1.29 |
Waist circumference was measured in standing position with a non-stretchable measuring tape to the nearest 0.1 centimeter (cm). Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| centimeter (cm) | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Waist Circumference at Week 48 | -4.71 ± 1.27 | -7.88 ± 1.28 | -10.64 ± 1.16 | -10.57 ± 1.22 | -13.60 ± 1.11 | -14.63 ± 0.90 | -16.55 ± 1.00 | -15.84 ± 1.10 | -19.03 ± 1.09 |
Waist circumference was measured in standing position with a non-stretchable measuring tape to the nearest 0.1 cm. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| centimeter (cm) | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Waist Circumference at Week 72 | -7.89 ± 1.32 | -9.59 ± 1.51 | -13.04 ± 1.30 | -10.40 ± 1.41 | -14.67 ± 1.33 | -15.59 ± 1.07 | -18.10 ± 1.24 | -18.21 ± 1.30 | -21.26 ± 1.26 |
Change from baseline in total body fat mass in kg was assessed by Dual energy X-ray absorptiometry (DXA). Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| Kilogram (kg) | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Total Body Fat Mass in Kilograms (kg) at Week 48 | -2.41 ± 0.76 | -6.90 ± 0.88 | -11.86 ± 1.03 | -7.49 ± 0.96 | -11.06 ± 0.86 | -14.17 ± 0.84 | -15.93 ± 0.85 | -15.33 ± 0.94 | -19.30 ± 0.82 |
Change from baseline in total body fat mass in kg was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| Kilogram (kg) | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Total Body Fat Mass in kg at Week 72 | -7.33 ± 0.87 | -7.84 ± 1.17 | -13.24 ± 1.19 | -7.66 ± 1.08 | -12.47 ± 1.07 | -15.85 ± 1.10 | -17.52 ± 1.13 | -16.72 ± 1.19 | -21.24 ± 1.13 |
Percent change from baseline for fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| Percent change | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline for Fat Mass by DXA at Week 48 | -5.53 ± 1.59 | -15.65 ± 1.97 | -25.23 ± 2.20 | -18.36 ± 2.28 | -24.57 ± 1.57 | -30.60 ± 1.70 | -35.85 ± 1.91 | -34.42 ± 2.02 | -42.06 ± 1.81 |
Percent change from baseline for fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| Percent change | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline for Fat Mass by DXA at Week 72 | -16.60 ± 2.11 | -18.45 ± 2.65 | -28.35 ± 2.45 | -18.97 ± 2.55 | -27.37 ± 2.11 | -33.58 ± 2.12 | -39.46 ± 2.46 | -37.26 ± 2.48 | -45.42 ± 2.12 |
Change from baseline in VAT, SAT and trunk fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| kg | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| VAT | -0.05 ± 0.06 | -0.36 ± 0.04 | -0.61 ± 0.06 | -0.30 ± 0.05 | -0.43 ± 0.05 | -0.64 ± 0.06 | -0.83 ± 0.07 | -0.75 ± 0.07 | -0.82 ± 0.06 |
| SAT | -0.13 ± 0.07 | -0.51 ± 0.10 | -0.87 ± 0.10 | -0.54 ± 0.07 | -0.80 ± 0.10 | -1.00 ± 0.07 | -1.15 ± 0.09 | -1.10 ± 0.10 | -1.37 ± 0.10 |
| Trunk fat mass | -1.24 ± 0.49 | -4.51 ± 0.53 | -7.65 ± 0.63 | -4.45 ± 0.61 | -6.31 ± 0.56 | -8.41 ± 0.48 | -9.97 ± 0.49 | -9.52 ± 0.63 | -11.52 ± 0.47 |
Change from baseline in VAT, SAT and trunk fat mass was assessed by DXA. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| Kilogram (kg) | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| VAT | -0.27 ± 0.07 | -0.39 ± 0.06 | -0.65 ± 0.06 | -0.33 ± 0.05 | -0.52 ± 0.05 | -0.67 ± 0.06 | -0.93 ± 0.09 | -0.74 ± 0.07 | -0.86 ± 0.07 |
| SAT | -0.47 ± 0.09 | -0.60 ± 0.12 | -0.98 ± 0.11 | -0.52 ± 0.09 | -0.91 ± 0.12 | -1.09 ± 0.10 | -1.25 ± 0.11 | -1.21 ± 0.13 | -1.51 ± 0.12 |
| Trunk Fat Mass | -4.55 ± 0.52 | -5.24 ± 0.67 | -8.61 ± 0.68 | -4.65 ± 0.67 | -7.30 ± 0.67 | -9.32 ± 0.63 | -11.06 ± 0.68 | -10.20 ± 0.78 | -12.86 ± 0.66 |
Waist circumference was measured in a standing position with a non-stretchable measuring tape to the nearest 0.1 cm. Only participants with non-missing baseline value were included in analysis.
| percentage of participants | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Reduction in Waist Circumference Greater Than or Equal to (≥) 5 cm at Week 48 | 45.7 | 71.0 | 78.4 | 66.7 | 82.4 | 95.1 | 100.0 | 90.7 | 97.7 |
Body weight was measured in kgs to the nearest 0.1 kg. Only participants with non-missing baseline value were included in analysis.
| percentage of participants | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Reduction in ≥ 5% | 40.0 | 58.1 | 83.8 | 73.3 | 92.2 | 97.6 | 100.0 | 97.7 | 97.7 |
| Reduction in ≥ 10% Body Weight | 8.6 | 29.0 | 51.4 | 48.9 | 80.4 | 68.3 | 92.5 | 81.4 | 95.3 |
| Reduction in ≥ 15% Body Weight | 5.7 | 16.1 | 32.4 | 35.6 | 47.1 | 41.5 | 55.0 | 60.5 | 79.1 |
Only participants with non-missing baseline value were included in analysis.
| percentage of participants | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| ≥ 5% reduction in Fat Mass | 43.3 | 93.3 | 97.2 | 80.0 | 97.9 | 100.0 | 100.0 | 100.0 | 100.0 |
| ≥ 10% reduction in Fat Mass | 23.3 | 90.0 | 88.9 | 64.4 | 91.5 | 97.6 | 97.5 | 97.6 | 100.0 |
| ≥ 15% reduction in Fat Mass | 10.0 | 53.3 | 75.0 | 53.3 | 85.1 | 92.9 | 97.5 | 90.5 | 100.0 |
Only participants with non-missing baseline value were included in analysis.
| percentage of participants | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Fat Mass ≥ 10% Reduction With <5% Decrease in Lean Mass by DXA at Week 48 | 16.7 | 83.3 | 77.8 | 26.7 | 19.1 | 61.9 | 65.0 | 76.2 | 67.4 |
Fat Lost Index = % change in fat mass/% change in lean mass + % change in fat mass. Only participants with non-missing baseline value were included in analysis.
| percentage of participants | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| >5kg Weight Loss and Fat Loss Index >70 % | 14.55 | 26.79 | 40.35 | 41.82 | 50.00 | 62.50 | 65.45 | 64.29 | 72.73 |
| >5kg Weight Loss and Fat Loss Index >80 % | 12.73 | 23.21 | 36.84 | 16.36 | 17.86 | 57.14 | 56.36 | 53.57 | 61.82 |
| >5kg Weight Loss and Fat Loss Index >90 % | 3.64 | 19.64 | 35.09 | 12.73 | 5.36 | 42.86 | 41.82 | 46.43 | 41.82 |
Change from baseline in body fat mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
| kg | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Body Fat Mass by Bioelectrical Impedance Analysis (BIA) at Week 48 | -2.72 ± 0.77 | -6.45 ± 0.78 | -9.84 ± 0.81 | -7.54 ± 0.93 | -10.83 ± 0.75 | -12.85 ± 0.69 | -14.71 ± 0.87 | -14.16 ± 0.82 | -16.87 ± 0.72 |
Change from baseline in body fat mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
| kg | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Body Fat Mass by BIA at Week 72 | -5.69 ± 0.87 | -7.20 ± 0.97 | -10.24 ± 1.00 | -6.49 ± 1.12 | -11.56 ± 0.95 | -13.94 ± 0.97 | -14.86 ± 0.92 | -14.95 ± 0.97 | -19.43 ± 0.97 |
Percent change from baseline in Body fat was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
| Percent change | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Body Fat by BIA at Week 48 | -1.49 ± 0.38 | -3.82 ± 0.45 | -5.70 ± 0.46 | -3.80 ± 0.65 | -5.18 ± 0.43 | -7.03 ± 0.42 | -8.47 ± 0.68 | -8.39 ± 0.61 | -9.33 ± 0.50 |
Percent change from baseline in Body fat was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
| Percent change | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Body Fat by BIA at Week 72 | -3.63 ± 0.45 | -4.36 ± 0.54 | -5.65 ± 0.57 | -3.06 ± 0.75 | -5.46 ± 0.56 | -7.43 ± 0.62 | -8.29 ± 0.66 | -8.71 ± 0.63 | -11.33 ± 0.84 |
Change from baseline in lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| kg | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Lean Mass by DXA at Week 48 | -0.33 ± 0.53 | 1.48 ± 0.51 | 1.19 ± 0.55 | -2.86 ± 0.45 | -4.43 ± 0.35 | -1.28 ± 0.42 | -1.12 ± 0.54 | -0.65 ± 0.66 | -1.43 ± 0.50 |
Change from baseline in lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| kg | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Lean Mass by DXA at Week 72 | 1.89 ± 0.72 | 2.26 ± 0.56 | 1.28 ± 0.58 | -2.78 ± 0.48 | -4.05 ± 0.45 | -1.04 ± 0.54 | -1.78 ± 0.52 | -0.79 ± 0.70 | -1.84 ± 0.57 |
Percent change from baseline in lean body mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| Percent change | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lean Body Mass by DXA at Week 48 | -0.54 ± 0.79 | 2.81 ± 0.84 | 2.39 ± 0.93 | -5.23 ± 0.79 | -7.90 ± 0.60 | -2.21 ± 0.78 | -1.92 ± 0.85 | -1.00 ± 1.01 | -2.51 ± 0.87 |
Percent change from baseline in lean body mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| Percent change | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lean Body Mass by DXA at Week 72 | 3.51 ± 1.14 | 4.17 ± 0.96 | 2.71 ± 0.96 | -5.09 ± 0.86 | -7.23 ± 0.79 | -1.96 ± 0.96 | -2.89 ± 0.81 | -1.38 ± 1.11 | -3.00 ± 1.00 |
Percent change from baseline in appendicular lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| Percent change | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Appendicular Lean Mass by DXA at Week 48 | -0.87 ± 0.82 | 3.07 ± 1.14 | 2.47 ± 0.96 | -5.68 ± 0.89 | -9.43 ± 0.77 | -2.31 ± 0.79 | -2.22 ± 0.91 | -1.74 ± 1.00 | -2.28 ± 0.99 |
Percent change from baseline in appendicular lean mass was assessed by DXA. Least Square mean was determined by mixed model repeated measures (MMRM) model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| Percent change | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Appendicular Lean Mass by DXA at Week 72 | 4.76 ± 1.47 | 4.98 ± 1.16 | 2.78 ± 1.15 | -6.24 ± 1.09 | -9.08 ± 0.87 | -2.30 ± 1.13 | -3.87 ± 0.86 | -2.29 ± 1.13 | -2.40 ± 1.29 |
Change from baseline in lean mass (kg) was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
| kg | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Lean Mass (kg) by BIA at Week 48 | -0.57 ± 0.38 | -0.13 ± 0.55 | -1.68 ± 0.46 | -3.40 ± 0.69 | -4.40 ± 0.44 | -2.73 ± 0.37 | -3.15 ± 0.52 | -2.73 ± 0.55 | -4.62 ± 0.48 |
Change from baseline in lean mass (kg) was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
| kg | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Lean Mass (kg) by BIA at Week 72 | 0.30 ± 0.49 | -0.54 ± 0.56 | -2.45 ± 0.62 | -4.34 ± 0.64 | -5.01 ± 0.45 | -3.32 ± 0.48 | -5.79 ± 1.11 | -3.95 ± 0.57 | -4.50 ± 0.82 |
Percent change from baseline in lean body mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
| Percent change | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lean Body Mass by BIA at Week 48 | 1.71 ± 0.52 | 3.62 ± 0.47 | 5.35 ± 0.47 | 4.02 ± 0.67 | 5.09 ± 0.40 | 6.83 ± 0.45 | 8.29 ± 0.69 | 7.23 ± 0.92 | 8.91 ± 0.50 |
Percent change from baseline in lean body mass was assessed through BIA. LS mean was determined using MMRM model for post-baseline measures: Variable is modelled by Treatment, Visit, Treatment-by-Visit interaction, Sex, and Country as fixed effects, with Baseline as a covariate. Variance-Covariance structure = Unstructured. Only participants with non-missing baseline value were included in the analysis.
| Percent change | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lean Body Mass by BIA at Week 72 | 2.29 ± 1.55 | 4.05 ± 0.57 | 4.65 ± 0.68 | 2.80 ± 1.17 | 4.66 ± 0.89 | 6.52 ± 1.41 | 6.89 ± 1.37 | 6.79 ± 1.34 | 10.64 ± 0.84 |
BMI categories: i. Healthy weight: 18.5 kilograms (kg)/meter (m)² to 24.9 kg/m² ii. Overweight: 25 kg/m² to 29.9 kg/m² iii. Obesity class 1: 30 kg/m² to 34.9 kg/m² iv. Obesity class II: 35 kg/m² to 39.9 kg/m² v. Obesity class III: ≥ 40 kg/m2
| percentage of participants | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Healthy weight (Baseline) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overweight (Baseline) | 1.8 | 5.4 | 1.8 | 14.5 | 5.4 | 3.6 | 9.1 | 1.8 | 5.5 |
| Obesity class I (Baseline) | 29.1 | 39.3 | 29.8 | 27.3 | 35.7 | 28.6 | 27.3 | 25.0 | 34.5 |
| Obesity class II (Baseline) | 40 | 30.4 | 38.6 | 27.3 | 32.1 | 30.4 | 29.1 | 50 | 27.3 |
| Obesity class III (Baseline) | 29.1 | 25 | 29.8 | 30.9 | 26.8 | 37.5 | 34.5 | 23.2 | 32.7 |
| Healthy weight (Week 48) | 0 | 0 | 2.7 | 17.8 | 3.9 | 2.4 | 10 | 7 | 11.6 |
| Overweight (Week 48) | 11.4 | 19.4 | 21.6 | 28.9 | 33.3 | 31.7 | 25 | 25.6 | 37.2 |
| Obesity class I (Week 48) | 37.1 | 32.3 | 43.2 | 17.8 | 51.0 | 31.7 | 37.5 | 53.5 | 27.9 |
| Obesity class II (Week 48) | 31.4 | 35.5 | 21.6 | 17.8 | 7.8 | 26.8 | 22.5 | 11.6 | 14 |
| Obesity class III (Week 48) | 20 | 12.9 | 10.8 | 17.8 | 3.9 | 7.3 | 5 | 2.3 | 9.3 |
WHtR ratio categories: \<0.5; 0.5-0.59; ≥0.6
No measurements were reported for this outcome.
WHtR ratio categories: \<0.5; 0.5-0.59; ≥0.6
| percentage of participants | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| WtHR Category: <0.5 | 0 | 0 | — | 50.0 | 0 | 0 | — | — | 25.0 |
| WtHR Category: 0.5-0.59 | 60.0 | 100.0 | — | 50.0 | 66.7 | 100.0 | — | — | 75.0 |
| WtHR Category: ≥0.6 | 40.0 | 0 | — | 0 | 33.3 | 0 | — | — | 0 |
WHtR ratio categories: \<0.5; 0.5-0.59; ≥0.6
| percentage of participants | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| WtHR Category: <0.5 | 0 | 0 | 5.4 | 2.6 | 2.1 | 0 | 7.7 | 2.3 | 15.4 |
| WtHR Category: 0.5-0.59 | 20.0 | 17.9 | 21.6 | 25.6 | 31.3 | 38.5 | 38.5 | 51.2 | 35.9 |
| WtHR Category: ≥0.6 | 80.0 | 82.1 | 73.0 | 71.8 | 66.7 | 61.5 | 53.8 | 46.5 | 48.7 |
HbA1c is the glycosylated fraction of hemoglobin A. It is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
| percentage of HbA1c | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 48 | -0.01 ± 0.05 | -0.20 ± 0.04 | -0.17 ± 0.06 | -0.34 ± 0.03 | -0.39 ± 0.03 | -0.37 ± 0.03 | -0.56 ± 0.04 | -0.44 ± 0.03 | -0.48 ± 0.03 |
The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores.
| t-score | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Quality of Life Short Form 36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score at Week 24 | 6.91 ± 2.33 | 9.74 ± 1.48 | 11.61 ± 1.62 | 11.50 ± 1.56 | 11.02 ± 1.97 | 12.20 ± 1.89 | 12.75 ± 1.92 | 12.71 ± 1.94 | 12.45 ± 1.93 |
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into (mental component score \[MCS\] and physical component score \[PCS\] to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.
| score on a scale | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score Week 24 | 6.47 ± 2.11 | 4.69 ± 1.98 | 9.70 ± 1.65 | 11.95 ± 1.56 | 12.26 ± 1.49 | 12.96 ± 2.02 | 10.09 ± 2.11 | 13.82 ± 1.62 | 13.31 ± 1.45 |
The SF-36v2 acute form assesses HRQoL on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10 items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores
| t-score | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 48 | 11.30 ± 1.80 | 11.72 ± 2.51 | 13.41 ± 1.64 | 11.68 ± 2.42 | 11.58 ± 2.14 | 16.34 ± 1.55 | 15.14 ± 1.82 | 15.27 ± 1.97 | 18.25 ± 2.19 |
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into MCS and PCS to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.
| score on a scale | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 48 | 10.02 ± 2.08 | 8.32 ± 2.00 | 11.31 ± 1.77 | 13.62 ± 1.79 | 14.27 ± 1.67 | 15.99 ± 1.90 | 16.42 ± 1.92 | 17.03 ± 1.60 | 17.69 ± 1.90 |
The SF-36v2 acute form assesses HRQoL on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10 items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores
| t-score | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Quality of Life SF-36v2 Acute Form Physical Functioning Domain Score Week 72 | 7.35 ± 3.81 | 13.70 ± 2.65 | 15.90 ± 1.62 | 14.06 ± 1.75 | 13.52 ± 2.28 | 17.36 ± 1.77 | 14.41 ± 1.97 | 17.04 ± 2.20 | 20.91 ± 1.76 |
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into MCS and PCS to obtain a total score ranging from 0 to 100, with higher scores indicating better levels of function and/or better health.
| score on a scale | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Quality of Life SF-36v2 Acute Form Total Score at Week 72 | 8.03 ± 3.49 | 6.96 ± 3.02 | 12.28 ± 1.91 | 13.84 ± 2.10 | 13.96 ± 2.04 | 16.98 ± 1.91 | 14.37 ± 2.12 | 18.26 ± 1.76 | 17.85 ± 1.59 |
The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'
| score on a scale | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Physical Function Score | 7.973 ± 15.919 | 13.289 ± 13.115 | 13.974 ± 13.726 | 16.667 ± 14.616 | 17.447 ± 16.677 | 14.659 ± 16.474 | 12.105 ± 22.680 | 18.690 ± 19.818 | 21.667 ± 17.113 |
| Total score | 8.142 ± 11.538 | 10.789 ± 10.363 | 15.513 ± 11.868 | 17.639 ± 11.285 | 19.468 ± 13.055 | 18.977 ± 14.901 | 14.671 ± 16.434 | 17.113 ± 14.463 | 22.917 ± 14.826 |
The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'
| score on a scale | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Physical Function Score | 13.45 ± 2.37 | 17.96 ± 2.37 | 19.39 ± 2.09 | 16.98 ± 2.07 | 21.39 ± 2.14 | 20.62 ± 2.62 | 23.21 ± 2.97 | 26.69 ± 2.30 | 22.96 ± 2.00 |
| Total Score | 13.44 ± 1.99 | 15.62 ± 1.92 | 18.52 ± 2.15 | 19.16 ± 1.98 | 23.43 ± 1.99 | 24.33 ± 2.11 | 22.91 ± 2.50 | 24.42 ± 2.18 | 26.47 ± 2.29 |
The IWQOL-Lite-CT is a 20-item, obesity-specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items). Each item is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning. The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning and quality of life. This endpoint shows results for 'physical function score' and 'total score.'
| score on a scale | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Physical Function Score | 12.08 ± 3.13 | 19.05 ± 2.58 | 19.34 ± 2.45 | 22.05 ± 1.80 | 25.07 ± 2.50 | 19.85 ± 2.10 | 19.30 ± 2.37 | 28.31 ± 2.79 | 29.85 ± 2.39 |
| Total Score | 14.08 ± 2.62 | 17.98 ± 2.69 | 19.12 ± 2.23 | 24.43 ± 1.91 | 25.46 ± 2.07 | 26.97 ± 2.41 | 21.47 ± 2.49 | 28.14 ± 2.78 | 32.19 ± 2.21 |
Collected over Baseline up to Week 104. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/30 mg/kg Bimagrumab | 0/55 (0%) | 5/55 (9.1%) | 46/55 (83.6%) |
| 10/30 mg/kg Bimagrumab | 0/56 (0%) | 9/56 (16.1%) | 54/56 (96.4%) |
| 30 mg/kg Bimagrumab | 0/57 (0%) | 8/57 (14%) | 54/57 (94.7%) |
| Placebo + 1.0 mg Semaglutide | 0/55 (0%) | 4/55 (7.3%) | 52/55 (94.5%) |
| Placebo + 2.4 mg Semaglutide | 0/56 (0%) | 8/56 (14.3%) | 52/56 (92.9%) |
| 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 0/56 (0%) | 7/56 (12.5%) | 53/56 (94.6%) |
| 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 0/55 (0%) | 8/55 (14.5%) | 54/55 (98.2%) |
| 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 0/56 (0%) | 6/56 (10.7%) | 54/56 (96.4%) |
| 30 mg/kg Bimagrumab + 2.4 mg Semaglutide | 0/55 (0%) | 7/55 (12.7%) | 54/55 (98.2%) |
| Event | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/55 | 0/56 | 0/57 | 0/55 | 0/56 | 0/56 | 0/55 | 0/56 | 2/55 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/55 | 0/56 | 2/57 | 1/55 | 0/56 | 0/56 | 0/55 | 0/56 | 1/55 |
| Transient ischaemic attackNervous system disorders | 0/55 | 0/56 | 2/57 | 0/55 | 0/56 | 0/56 | 0/55 | 0/56 | 0/55 |
| DiarrhoeaGastrointestinal disorders | 0/55 | 0/56 | 0/57 | 0/55 | 0/56 | 0/56 | 1/55 | 0/56 | 0/55 |
| Mallory-weiss syndromeGastrointestinal disorders | 1/55 | 0/56 | 0/57 | 0/55 | 0/56 | 0/56 | 0/55 | 0/56 | 0/55 |
| Obstructive pancreatitisGastrointestinal disorders | 1/55 | 0/56 | 0/57 | 0/55 | 0/56 | 0/56 | 0/55 | 0/56 | 0/55 |
| PancreatitisGastrointestinal disorders | 0/55 | 1/56 | 0/57 | 1/55 | 0/56 | 0/56 | 0/55 | 0/56 | 0/55 |
| Chest painGeneral disorders | 0/55 | 0/56 | 0/57 | 0/55 | 0/56 | 0/56 | 1/55 | 0/56 | 0/55 |
| Cholecystitis acuteHepatobiliary disorders | 0/55 | 0/56 | 0/57 | 0/55 | 0/56 | 0/56 | 1/55 | 0/56 | 0/55 |
| CholelithiasisHepatobiliary disorders | 0/55 | 1/56 | 0/57 | 0/55 | 1/56 | 1/56 | 0/55 | 1/56 | 1/55 |
| Event | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide |
|---|---|---|---|---|---|---|---|---|---|
| Muscle spasmsMusculoskeletal and connective tissue disorders | 22/55 | 27/56 | 41/57 | 8/55 | 6/56 | 32/56 | 36/55 | 36/56 | 35/55 |
| NauseaGastrointestinal disorders | 9/55 | 15/56 | 8/57 | 25/55 | 26/56 | 23/56 | 34/55 | 20/56 | 27/55 |
| AcneSkin and subcutaneous tissue disorders | 20/55 | 22/56 | 28/57 | 7/55 | 6/56 | 24/56 | 25/55 | 31/56 | 29/55 |
| DiarrhoeaGastrointestinal disorders | 10/55 | 27/56 | 29/57 | 19/55 | 21/56 | 27/56 | 29/55 | 25/56 | 27/55 |
| Covid-19Infections and infestations | 11/55 | 17/56 | 16/57 | 15/55 | 18/56 | 12/56 | 12/55 | 10/56 | 12/55 |
| Upper respiratory tract infectionInfections and infestations | 11/55 | 13/56 | 13/57 | 14/55 | 17/56 | 11/56 | 10/55 | 16/56 | 17/55 |
| ConstipationGastrointestinal disorders | 3/55 | 2/56 | 3/57 | 11/55 | 16/56 | 8/56 | 15/55 | 17/56 | 9/55 |
| FatigueGeneral disorders | 3/55 | 4/56 | 4/57 | 13/55 | 15/56 | 7/56 | 11/55 | 8/56 | 12/55 |
| HeadacheNervous system disorders | 8/55 | 11/56 | 7/57 | 10/55 | 13/56 | 10/56 | 12/55 | 13/56 | 9/55 |
| Abdominal painGastrointestinal disorders | 4/55 | 2/56 | 4/57 | 4/55 | 6/56 | 7/56 | 7/55 | 5/56 | 10/55 |
All randomized participants.
| Age, Continuous(years) | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 47.8 ± 14.6 | 44.4 ± 10.9 | 49.2 ± 12.2 | 50.3 ± 11.2 | 49.6 ± 11.8 | 44.8 ± 12.0 | 46.2 ± 11.7 | 47.7 ± 10.4 | 47.5 ± 12.7 | 47.5 ± 12.1 |
| Sex: Female, Male(Participants) | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 32 | 32 | 33 | 32 | 33 | 32 | 32 | 32 | 33 | 291 |
| Male | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 216 |
| Ethnicity (NIH/OMB)(Participants) | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 11 | 3 | 4 | 2 | 5 | 7 | 7 | 8 | 53 |
| Not Hispanic or Latino | 48 | 44 | 53 | 52 | 54 | 50 | 49 | 47 | 48 | 445 |
| Unknown or Not Reported | 2 | 1 | 1 | 0 | 1 | 1 | 0 | 2 | 1 | 9 |
| Race/Ethnicity, Customized(Participants) | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 3 |
| Asian | 1 | 1 | 1 | 0 | 3 | 1 | 4 | 1 | 3 | 15 |
| Black | 6 | 3 | 4 | 7 | 5 | 7 | 5 | 6 | 3 | 46 |
| Native Hawaiian or Other Pacific Islander | 5 | 3 | 2 | 1 | 1 | 2 | 6 | 3 | 1 | 24 |
| Other | 6 | 4 | 4 | 7 | 2 | 5 | 2 | 3 | 3 | 36 |
| White | 38 | 44 | 45 | 40 | 46 | 41 | 39 | 43 | 45 | 381 |
| Multiple | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Region of Enrollment(Participants) | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Australia | 12 | 8 | 17 | 9 | 19 | 5 | 7 | 14 | 14 | 105 |
| New Zealand | 24 | 24 | 23 | 26 | 23 | 25 | 30 | 24 | 23 | 222 |
| United States | 20 | 24 | 17 | 21 | 15 | 26 | 19 | 18 | 20 | 180 |
| Body Weight(kilogram (kg)) | Placebo/30 mg/kg Bimagrumab | 10/30 mg/kg Bimagrumab | 30 mg/kg Bimagrumab | Placebo + 1.0 mg Semaglutide | Placebo + 2.4 mg Semaglutide | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 109.55 ± 19.33 | 105.12 ± 19.50 | 109.05 ± 17.56 | 105.81 ± 20.02 | 104.50 ± 14.82 | 108.36 ± 18.92 | 108.78 ± 18.41 | 108.19 ± 14.34 | 108.12 ± 18.48 | 107.50 ± 17.97 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Nov 2022 to primary completion in May 2024, 18 months.
Results were first posted in Jul 2025, 1 year 2 months after primary completion.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 18 months is above that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimagrumab